Repotrectinib
CA127-1030
Phase 3 small_molecule active
Quick answer
Repotrectinib for Carcinoma, Non-Small-Cell Lung is a Phase 3 program (small_molecule) at Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb
- Indication
- Carcinoma, Non-Small-Cell Lung
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active